CIDARA THERAPEUTICS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 12.02 USD | +0.84% |
|
+7.23% | -24.31% |
| May. 15 | Earnings Flash (CDTX) CIDARA THERAPEUTICS Posts Q1 Revenue $8.5M | MT |
| Apr. 25 | Top Premarket Gainers | MT |
Valuation
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 126.9 | 87.88 | 84.69 | 54.16 | 71.8 | 54.38 | - | - |
| Enterprise Value (EV) 1 | 126.9 | 87.88 | 84.69 | 54.16 | 71.8 | 54.38 | 54.38 | 54.38 |
| P/E ratio | -2.72 x | -1.11 x | -1.57 x | -1.76 x | -3.05 x | -0.68 x | 23.5 x | 3.76 x |
| Yield | - | - | - | - | - | - | - | - |
| Capitalization / Revenue | 6.07 x | 7.28 x | 1.71 x | 0.84 x | 1.12 x | 4.46 x | 1.27 x | 1.02 x |
| EV / Revenue | 6.07 x | 7.28 x | 1.71 x | 0.84 x | 1.12 x | 4.46 x | 1.27 x | 1.02 x |
| EV / EBITDA | - | - | - | - | - | - | - | - |
| EV / FCF | - | - | - | - | -3.78 x | -0.56 x | -0.6 x | -0.57 x |
| FCF Yield | - | - | - | - | -26.5% | -178% | -167% | -176% |
| Price to Book | - | - | - | - | - | - | - | - |
| Nbr of stocks (in thousands) | 1,652 | 2,197 | 3,334 | 3,581 | 4,522 | 4,562 | - | - |
| Reference price 2 | 76.80 | 40.00 | 25.40 | 15.13 | 15.88 | 11.92 | 11.92 | 11.92 |
| Announcement Date | 3/4/20 | 2/25/21 | 3/7/22 | 3/23/23 | 4/22/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 20.92 | 12.07 | 49.57 | 64.29 | 63.9 | 12.2 | 42.86 | 53.25 |
| EBITDA | - | - | - | - | - | - | - | - |
| EBIT 1 | -41.72 | -71.85 | -42.26 | -29.72 | -24.48 | -87 | -40.59 | -33.98 |
| Operating Margin | -199.49% | -595.42% | -85.24% | -46.23% | -38.31% | -713.11% | -94.72% | -63.82% |
| Earnings before Tax (EBT) 1 | -41.09 | -72.11 | -42.47 | -29.53 | -22.49 | -85 | -39.43 | -33.32 |
| Net income 1 | -41.09 | -74.87 | -42.47 | -29.8 | -22.93 | -85 | -39.43 | -33.32 |
| Net margin | -196.47% | -620.48% | -85.67% | -46.35% | -35.88% | -696.72% | -92% | -62.57% |
| EPS 2 | -28.20 | -36.00 | -16.20 | -8.600 | -5.200 | -17.49 | 0.5067 | 3.173 |
| Free Cash Flow 1 | - | - | - | - | -19.02 | -97 | -90.75 | -95.45 |
| FCF margin | - | - | - | - | -29.76% | -795.08% | -211.75% | -179.26% |
| FCF Conversion (EBITDA) | - | - | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - | - | - |
| Announcement Date | 3/4/20 | 2/25/21 | 3/7/22 | 3/23/23 | 4/22/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 7.225 | 7.109 | 6.216 | 40.74 | 10.22 | 25.99 | 7.614 | 12.72 | 17.58 | 8.463 | 1.3 | 1.3 | 1.2 |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - |
| EBIT 1 | -16.77 | -18.26 | -13.11 | 14.92 | -13.27 | 2.977 | -12.83 | -8.555 | -3.676 | -10.69 | -19.8 | -25.8 | -30.8 |
| Operating Margin | -232.11% | -256.87% | -210.96% | 36.63% | -129.83% | 11.45% | -168.52% | -67.27% | -20.91% | -126.33% | -1,523.08% | -1,984.62% | -2,566.67% |
| Earnings before Tax (EBT) 1 | -16.8 | -18.28 | -13.12 | 14.98 | -13.1 | 3.209 | -12.21 | -7.942 | -3.149 | -10.33 | -19.3 | -25.3 | -30.2 |
| Net income 1 | -16.8 | -18.28 | -13.12 | 11.9 | -13.38 | 2.532 | -12.36 | -8.172 | -3.213 | -10.33 | -19.3 | -25.3 | -30.2 |
| Net margin | -232.57% | -257.15% | -211.05% | 29.2% | -130.9% | 9.74% | -162.29% | -64.26% | -18.27% | -122.01% | -1,484.62% | -1,946.15% | -2,516.67% |
| EPS 2 | -5.600 | -5.400 | -3.800 | 3.400 | -3.800 | 0.6000 | -2.800 | -1.800 | -0.8000 | -2.280 | -4.100 | -5.050 | -5.800 |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 3/7/22 | 5/11/22 | 8/9/22 | 11/3/22 | 3/23/23 | 5/11/23 | 8/3/23 | 11/2/23 | 4/22/24 | 5/15/24 | - | - | - |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net Debt | - | - | - | - | - | - | - | - |
| Net Cash position | - | - | - | - | - | - | - | - |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - | - |
| Free Cash Flow 1 | - | - | - | - | -19 | -97 | -90.8 | -95.5 |
| ROE (net income / shareholders' equity) | - | - | - | - | - | - | - | - |
| ROA (Net income/ Total Assets) | - | - | - | - | - | - | - | - |
| Assets 1 | - | - | - | - | - | - | - | - |
| Book Value Per Share | - | - | - | - | - | - | - | - |
| Cash Flow per Share | - | - | - | - | - | - | - | - |
| Capex 1 | 0.04 | 0.19 | 0.04 | 0.12 | 0.51 | 0.5 | 0.5 | 0.5 |
| Capex / Sales | 0.17% | 1.54% | 0.08% | 0.18% | 0.79% | 4.1% | 1.17% | 0.94% |
| Announcement Date | 3/4/20 | 2/25/21 | 3/7/22 | 3/23/23 | 4/22/24 | - | - | - |
1USD in Million
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
C-
Sell
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
11.92
USD
Average target price
25
USD
Spread / Average Target
+109.73%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -24.94% | 54.38M | |
| +10.79% | 116B | |
| +11.65% | 106B | |
| -6.20% | 23.89B | |
| -3.29% | 21.58B | |
| -11.39% | 18.96B | |
| -13.41% | 16.33B | |
| -40.50% | 16.96B | |
| +6.64% | 14.14B | |
| +31.84% | 12.02B |
- Stock Market
- Equities
- CDTX Stock
- Financials Cidara Therapeutics, Inc.
